This year marks two decades of development and production of high purity seaweed extracts for Marinova, a global leader in the research, development and manufacture of fucoidan compounds—highly bioactive polysaccharides derived from select species of brown seaweed.

Coinciding with the 20th anniversary, Marinova is undertaking a $4.6 million expansion of its state-of-the-art fucoidan extraction facility in Tasmania, Australia. The significant capital expansion will allow the company to triple its fucoidan production capacity in line with rising global demand.

“The unrivalled quality and efficacy of Marinova’s bioactive fucoidan extracts is based on two decades of rigorous scientific investigation and the development of the unique Maritech extraction process,” said CEO Paul Garrott. “It is by virtue of this proprietary process that Marinova remains the world’s only producer of high purity, certified organic fucoidan with global regulatory acceptance.”

The company’s fucoidan extracts are exported to over 35 countries for inclusion in nutritional, cosmetic and animal health applications. The high purity fucoidan fractions are also utilized in medical devices and form the basis of pharmaceutical research.

Marinova has accelerated scientific research into the bioactive properties of its unique fucoidan extracts. “Marinova has always invested significantly in scientific research and has recently extended its research commitment by a further $5 million over the coming years,” said Garrott. “Natural, certified organic, efficacious, and sustainably sourced ingredients that are supported by an extensive scientific dossier of scientific evidence are rare—and in high global demand. Marinova’s commitment to science remains unwavering.”